Journal of Gastroenterology

, Volume 50, Issue 4, pp 445–454 | Cite as

A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis

  • Do Seon Song
  • Myeong Jun Song
  • Si Hyun Bae
  • Woo Jin Chung
  • Jae Young Jang
  • Young Seok Kim
  • Sae Hwan Lee
  • Jun Yong Park
  • Hyung Joon Yim
  • Sung Bum Cho
  • Soo Young Park
  • Jin Mo Yang
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

The aim of this study was to compare the efficacy of hepatic arterial infusion chemotherapy (HAIC) and sorafenib in advanced hepatocellular carcinoma (HCC) patients with portal vein tumor thrombosis (PVTT).

Methods

A total of 110 patients were observed between February 2008 and May 2013 in seven Korean centers. Fifty patients were treated with HAIC, and 60 patients were treated with sorafenib.

Results

The disease control rate in the HAIC was significantly higher than that in the sorafenib group (p < 0.001), although there was no significant difference in the objective response rate (p = 0.214). The median overall survival (OS) was significantly longer in the HAIC group than in the sorafenib group (7.1 vs. 5.5 months, p = 0.011). The median time to-progression (TTP) was also significantly longer in the HAIC group than in the sorafenib group (3.3 vs. 2.1 months, p = 0.034). In the multivariate analysis, tumor diameter (≥ 10 cm) and the absence of combined loco-regional treatment were significant prognostic factors influencing OS (p = 0.002 and p = 0.010, respectively) and TTP (p = 0.017 and p = 0.006, respectively). The treatment modality tended to be a significant prognostic factor for survival (p = 0.052), but not for tumor progression (p = 0.121).

Conclusions

HAIC is comparable with sorafenib in terms of OS and TTP in advanced HCC patients with PVTT. HAIC shows more favorable treatment responses compared with sorafenib. Therefore, HAIC might be an alternative treatment modality to sorafenib in advanced HCC patients with PVTT.

Keywords

Hepatic arterial infusion chemotherapy Sorafenib Hepatocellular carcinoma Portal vein tumor thrombosis 

Notes

Acknowledgments

This work was supported by a National R & D Program grant for cancer control from the Ministry of Health, Welfare, and Family Affairs, Republic of Korea (R0620390-1).

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

535_2014_978_MOESM1_ESM.docx (15 kb)
Supplementary material 1 (DOCX 15 kb)

References

  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J cancer. 2010;127(12):2893–917 Epub 2011/02/26.CrossRefPubMedGoogle Scholar
  2. 2.
    Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(7):417–22 Epub 2004/03/26.CrossRefPubMedGoogle Scholar
  3. 3.
    Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 2003;37(2):429–42 Epub 2003/01/24.CrossRefPubMedGoogle Scholar
  4. 4.
    Pirisi M, Avellini C, Fabris C, Scott C, Bardus P, Soardo G, et al. Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. J Cancer Res Clin Oncol. 1998;124(7):397–400 Epub 1998/08/27.CrossRefPubMedGoogle Scholar
  5. 5.
    Villa E, Moles A, Ferretti I, Buttafoco P, Grottola A, Del Buono M, et al. Natural history of inoperable hepatocellular carcinoma: estrogen receptors’ status in the tumor is the strongest prognostic factor for survival. Hepatology. 2000;32(2):233–8 Epub 2000/08/01.CrossRefPubMedGoogle Scholar
  6. 6.
    Llovet JM, Bustamante J, Castells A, Vilana R, Ayuso Mdel C, Sala M, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29(1):62–7 Epub 1998/12/24.CrossRefPubMedGoogle Scholar
  7. 7.
    Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2 Epub 2011/03/05.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    EASL-EORTC. Clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–43 Epub 2012/03/20.CrossRefGoogle Scholar
  9. 9.
    Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Intl. 2010;4(2):439–74 Epub 2010/09/10.CrossRefGoogle Scholar
  10. 10.
    Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34 Epub 2008/12/20.CrossRefPubMedGoogle Scholar
  11. 11.
    Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J of Med. 2008;359(4):378–90 Epub 2008/07/25.CrossRefGoogle Scholar
  12. 12.
    Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee do Y, et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer. 2007;110(1):129–37 Epub 2007/05/18.CrossRefPubMedGoogle Scholar
  13. 13.
    Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, et al. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer. 2002;95(3):588–95 Epub 2002/09/05.CrossRefPubMedGoogle Scholar
  14. 14.
    Kim HY, Kim JD, Bae SH, Park JY, Han KH, Woo HY, et al. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma. Korean J Hepatol. 2010;16(4):355–61 Epub 2011/03/19.CrossRefPubMedCentralPubMedGoogle Scholar
  15. 15.
    Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW, Chang JC. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol. 2009;44(12):1477–86 Epub 2009/12/05.CrossRefPubMedGoogle Scholar
  16. 16.
    Hiramine Y, Uto H, Imamura Y, Tabu K, Baba Y, Hiwaki T, et al. Sorafenib and hepatic arterial infusion chemotherapy for unresectable advanced hepatocellular carcinoma: A comparative study. Exp Ther Med. 2011;2(3):433–41 Epub 2011/05/01.PubMedCentralPubMedGoogle Scholar
  17. 17.
    Jeong SW, Jang JY, Lee JE, Lee SH, Kim SG, Cha SW, et al. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 2012;8(2):164–71 Epub 2012/04/25.CrossRefPubMedGoogle Scholar
  18. 18.
    Song do S, Bae SH. Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period. Clin Mol Hepatol. 2012;18(3):258–67 Epub 2012/10/24.CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Korean Liver Cancer Study Group, National Cancer Center. Practice guidelines for managemeQuerynt of hepatocellular carcinoma 2009. Korean J. Hepatol. 2009;15(3):391–423. Epub 2009/09/29.Google Scholar
  20. 20.
    Woo HY, Bae SH, Park JY, Han KH, Chun HJ, Choi BG, et al. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2010;65(2):373–82 Epub 2009/09/19.CrossRefPubMedGoogle Scholar
  21. 21.
    Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52–60 Epub 2010/02/23.CrossRefPubMedGoogle Scholar
  22. 22.
    National Cancer Institute C. Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Available from: URL: http://ctep.cancer.gov. Available from: http://ctep.cancer.gov.
  23. 23.
    Shao YY, Huang CC, Liang PC, Lin ZZ. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 2010;6(2):80–8 Epub 2010/06/23.CrossRefPubMedGoogle Scholar
  24. 24.
    Lai YC, Shih CY, Jeng CM, Yang SS, Hu JT, Sung YC, et al. Hepatic arterial infusion chemotherapy for hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2003;9(12):2666–70 Epub 2003/12/12.PubMedGoogle Scholar
  25. 25.
    Song do S, Bae SH, Song MJ, Lee SW, Kim HY, Lee YJ, et al. Hepatic arterial infusion chemotherapy in hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2013;19(29):4679–88 Epub 2013/08/08.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Obi S, Yoshida H, Toune R, Unuma T, Kanda M, Sato S, et al. Combination therapy of intraarterial 5-fluorouracil and systemic interferon-alpha for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2006;106(9):1990–7 Epub 2006/03/28.CrossRefPubMedGoogle Scholar
  27. 27.
    Yau T, Chan P, Ng KK, Chok SH, Cheung TT, Fan ST, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer. 2009;115(2):428–36 Epub 2008/12/25.CrossRefPubMedGoogle Scholar
  28. 28.
    Nagano H, Wada H, Kobayashi S, Marubashi S, Eguchi H, Tanemura M, et al. Long-term outcome of combined interferon-alpha and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology. 2011;80(1–2):63–9 Epub 2011/06/11.CrossRefPubMedGoogle Scholar
  29. 29.
    Park HC, Seong J, Tanaka M, Zeng ZC, Lim HY, Guan S, et al. Multidisciplinary management of nonresectable hepatocellular carcinoma. Oncology. 2011;81(Suppl 1):134–40 Epub 2012/01/11.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  • Do Seon Song
    • 1
    • 2
    • 3
  • Myeong Jun Song
    • 1
    • 2
    • 3
  • Si Hyun Bae
    • 1
    • 2
    • 3
  • Woo Jin Chung
    • 1
    • 4
  • Jae Young Jang
    • 1
    • 5
  • Young Seok Kim
    • 1
    • 5
  • Sae Hwan Lee
    • 1
    • 5
  • Jun Yong Park
    • 1
    • 6
  • Hyung Joon Yim
    • 1
    • 7
  • Sung Bum Cho
    • 1
    • 8
  • Soo Young Park
    • 1
    • 9
  • Jin Mo Yang
    • 1
    • 2
    • 3
  1. 1.The Korean Liver Cancer Study GroupSeoulKorea
  2. 2.The Catholic University Liver Research CenterSeoulKorea
  3. 3.Division of Hepatology, Department of Internal Medicine, College of MedicineThe Catholic University of KoreaSeoulKorea
  4. 4.Department of Internal MedicineKeimyung University School of MedicineDaeguSouth Korea
  5. 5.Department of Internal MedicineSoonchunhyang University College of MedicineAnsanSouth Korea
  6. 6.Department of Internal MedicineYonsei University College of MedicineSeoulSouth Korea
  7. 7.Department of Internal MedicineKorea UniversitySeoulSouth Korea
  8. 8.Department of Internal MedicineHwasoon Chonnam National University HospitalGwangjuSouth Korea
  9. 9.Department of Gastroenterology and HepatologyKyungpook National University HospitalDaeguSouth Korea

Personalised recommendations